ClinicalTrials.gg
RecruitingNCT07746141Updated Oct 23, 2026

A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations

A Phase 1 interventional study of BG-85738 and Tislelizumab in RAS Mutation, Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by BeOne Medicines. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 23, 2026First site in New Zealand1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 260 studies in Neoplasm Metastasis with a site in Australia — 61 open to participants now, 106 under way, 34 of them phase 3. Neoplasm Metastasis · Australia.

Planned enrollment
174th of 253
100 · median 227
Started
2026
with 12 others
Phase 1
67 of 260
20 open now
Primary completion
2028-09
later than 81 of 105 live
Registered
260th of 260
by date

Among the 260 studies in Neoplasm Metastasis with a site in Australia, this one is the 174th largest by planned enrollment of the 253 interventional ones that give a count, is one of 13 that started in 2026, is one of 67 in phase 1, reaches primary completion later than 81 of the 105 other live ones, and was the 260th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 892 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

61 of the 260 studies in Neoplasm Metastasis with a site in Australia are open now. Recruiting first, the newest first:

55 more — sign in →

All 61 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Neoplasm Metastasis with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.

Read the detailed description

A solid tumor is an abnormal mass of tissue caused by the uncontrolled growth of cells which can develop in organs, bones, or soft tissues. An advanced or metastatic solid tumor is a cancer that has either grown into nearby tissues ("advanced") or spread to distant parts of the body ("metastatic").

Many types of solid cancers have a change (mutation) in a gene called RAS gene. In normal cells, RAS proteins work by controlling when cells grow and divide. RAS mutations in cancer cells might lead to hyperactivation of the RAS proteins, which can result in continuous and uncontrolled growth of cancer cells. BG-85738 is a new experimental medicine that has been designed to block RAS proteins that are hyperactive.

The purpose of this study is to test whether BG-85738 is safe and if it can help to treat adults with advanced or metastatic solid tumors with a RAS mutation. This study has two parts, one called dose escalation, and one called safety expansion. During the dose escalation part, the study doctors will test different doses of the study drug[s] to find the recommended dose that people can take without having serious side effects.

During the dose expansion part, the study doctors will test the study drug in a larger number of people using the dose[s] identified from dose escalation.

The study will enroll patients at multiple centers worldwide who have been diagnosed with an advanced solid tumor that has a RAS gene mutation. The overall time to participate in this study is approximately 13 to 24 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and for tumor and imaging tests.

03

Conditions studied

  • RAS Mutation
  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if they meet all the following criteria:

  • Participants must sign the form and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Participants must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place, whichever is older), at the time of signing the ICF.
  • Participants with or cytologically confirmed advanced, , and unresectable solid tumors and meet study part and cohort-specific criteria
  • Participants must have evidence of a RAS mutation defined as a nonsynonymous mutation in Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), or Harvey rat sarcoma viral oncogene homolog (HRAS) at codons 12, 13, or 61 (G12, G13, or Q61), based on testing of either tumor tissue or liquid (blood or plasma) as determined by the local laboratory

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if they meet any of the following criteria:

  • Participants who have prior RAS-targeted therapy, including, but not limited to, KRAS mutation-specific inhibitors (with the exception of participants with NSCLC and colorectal cancer who received a G12C inhibitor), pan-KRAS inhibitors, and pan-RAS inhibitors.
  • Participants who have a history of severe allergic reactions or to the active ingredient and of study treatment.
  • Participants who are unable to comply with the requirements of the protocol.
  • Participants with active or uncontrolled, untreated
  • Participants with any ≤ 3 years before the first dose of study treatment except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast).
  • Participants with active .
  • Participants with medical history of untreated infection.

Note: Other protocol defined criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Phase 1a: Part A- Monotherapy Dose escalation and safety

    Ascending dose levels of BG-85738 will be evaluated as monotherapy in participants with advanced or metastatic solid tumors with RAS mutations.

    Drug: BG-85738

  • Experimental
    Phase 1a: Part B - Combination therapy Dose escalation

    Sequential dose levels of BG-85738, selected based on Part A data, will be evaluated in combination with tislelizumab or in combination with cetuximab.

    Drug: BG-85738 · Drug: Tislelizumab · Drug: Cetuximab

  • Experimental
    Phase 1b: Part C- Monotherapy dose expansion

    Participants with selected tumor types will receive BG-85738 monotherapy at the RDFE(s) identified in Phase 1a Part A.

    Drug: BG-85738

  • Experimental
    Phase 1b: Part D - Combination therapy dose expansion

    Participants with select tumor types will receive BG-85738 in combination with tislelizumab or in combination with cetuximab at the RDFE(s) identified in Phase 1a Part B

    Drug: BG-85738 · Drug: Tislelizumab · Drug: Cetuximab

Interventions

  • DrugBG-85738

    Administered orally

  • Administered intravenously

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Phase 1a (Part A and Part B): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporarily associated with the use of study treatment, whether considered related to study treatment or not. An SAE is any untoward medical occurrence that, at any dose, * Results in death * Is life-threatening * Requires hospitalization or prolongation of existing hospitalization * Results in disability/incapacity * Is congenital anomaly/birth defect * Is considered a significant medical AE by the investigator based on medical judgement

    Time frame: From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 24 months

  2. Phase 1a (Parts A and B): Number of Participants with Dose Limiting Toxicity (DLT)

    Time frame: Up to approximately 1 month

  3. Phase 1a (Parts A and B): Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-85738 as monotherapy or in combination with other antitumor agents

    MTD is defined as the highest dose level with the target DLT closest but not exceeding 0.33. MAD is defined as the maximum administered dose and it is used when MTD is not reached.

    Time frame: Up to approximately 1 month

  4. Phase 1a: Recommended Dose for Expansion (RDFE) of BG-85738

    Time frame: Up to approximately 1 month

  5. Part 1b (Parts C and D): Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). * CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. * PR: A ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 24 months

  6. Phase 1b Dose Expansion: Recommended Phase 2 dose (RP2D) of BG-85738

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Phase 1a (Part A and Part B): Terminal Half Life (t1/2) of BG-85738

    Time frame: Up to approximately 2 months

  2. Phase 1a (Part A and Part B): Area Under the Plasma Concentration-Time Curve (AUC) of BG-85738

    Time frame: Up to approximately 2 months

  3. Phase 1a (Part A and Part B): Minimum Observed Serum Concentration (Ctrough) of BG-85738

    Time frame: Up to approximately 2 months

  4. Phase 1a (Part A and Part B): Maximum Observed Plasma Concentration (Cmax) of BG-85738

    Time frame: Up to approximately 2 months

  5. Phase 1a (Part A and Part B): Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). * CR: Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. * PR: A ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to approximately 24 months

  6. Phase 1b (Parts C and D): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporarily associated with the use of study treatment, whether considered related to study treatment or not. An SAE is any untoward medical occurrence that, at any dose, * Results in death * Is life-threatening * Requires hospitalization or prolongation of existing hospitalization * Results in disability/incapacity * Is congenital anomaly/birth defect * Is considered a significant medical AE by the investigator based on medical judgement

    Time frame: From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 24 months

  7. Phase 1b (Part C and D): Duration of response (DOR)

    DOR is defined as the time from the first determination of an overall response until the first documentation of progression or death, whichever comes first.

    Time frame: Up to approximately 24 months

  8. Phase 1b (Part C and D): Disease control rate (DCR)

    DCR is defined as the percentage of participants with best of response of a CR, PR, and stable disease.

    Time frame: Up to approximately 24 months

  9. Phase 1b (Part C and D): Time to response (TTR)

    TTR is defined as the time from date of the first dose of study treatment to the first overall response.

    Time frame: Up to approximately 24 months

  10. Phase 1b (Part C and D): Progression-free survival (PFS) as assessed by the investigator

    PFS is defined as the time from the date of the first dose of study treatment to the date of the first documentation of progressive disease or death, whichever occurs first, as assessed by the investigator per RECIST v1.1

    Time frame: Up to approximately 24 months

  11. Phase 1b (Part C): Intracranial Objective Response Rate (iORR)

    Intracranial objective response rate is defined as the percentage of patients with a best overall Intracranial response of CR or PR according to modified (m)RECIST v1.1 per Investigator assessment.

    Time frame: Up to approximately 24 months

  12. Phase 1b (Part C): Intracranial Duration of Response (iDOR)

    iDOR is defined as the time from the first determination of an overall intracranial response until the first documentation of progression or death, whichever comes first, with intracranial assessments by the investigator via modified RECIST v1.1 adapted for brain metastases.

    Time frame: Up to approximately 24 months

  13. Phase 1b (Part C): Intracranial Progression-free survival (iPFS) as determined from tumor assessments by the investigator

    iPFS is defined as the time from the date of the first dose of study treatment to the date of the first documentation of progressive disease or death, whichever occurs first. PFS is determined from tumor assessments by the investigator per a modified RECIST v1.1 adapted for brain metastases

    Time frame: Up to approximately 24 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 4, 2026
StartActual
Sep 2, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in New Zealand
Show site
  • Auckland City Hospital · Auckland, New Zealand
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added — first site in New Zealand
    Show site
    • Auckland City Hospital · Auckland, New Zealand

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07746141
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Sep 2, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Study Director
Contact
clinicaltrials@beonemed.com
877-828-5568
Study Director
study director · BeOne Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion